About Us

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries).

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

https://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Large.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Small.jpg
https://arcturusrx.com/wp-content/uploads/2024/04/Arcturus_Team_4-29-24.jpg
https://arcturusrx.com/wp-content/uploads/2024/04/Group-photo-July-2023_Final-1.png
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/ArcBuilding_Final.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/building_external_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-exterior.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main_office_exterior_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-interior-tag-line.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/building_tagline_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo-scaled-1.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo-scaled-1.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo_thumbnail.jpg
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
October 25, 2023
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
READ MORE
November 14, 2023
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
READ MORE
November 27, 2023
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
READ MORE
November 28, 2023
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
READ MORE
December 4, 2023
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
READ MORE
December 21, 2023
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
READ MORE
February 5, 2024
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
READ MORE
February 20, 2024
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
READ MORE
February 22, 2024
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
READ MORE
February 26, 2024
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
READ MORE
March 7, 2024
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
READ MORE
April 25, 2024
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
READ MORE
May 8, 2024
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
READ MORE
May 15, 2024
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
READ MORE
May 20, 2024
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
READ MORE
May 28, 2024
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
READ MORE
June 7, 2024
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
READ MORE
June 20, 2024
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
READ MORE
July 1, 2024
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
READ MORE
July 18, 2024
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
READ MORE